Autres langues Pacira BioSciences, Inc.

Actions

PCRX

US6951271005

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
26,33 ^USD	+3,25%		+0,30%	-21,96%

13/03	Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
13/03	Pacira BioSciences annonce que la FDA américaine a accordé à son produit candidat de thérapie de l'arthrose du genou la désignation RMAT	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Los bancos occidentales advierten de los riesgos del plan de la UE para usar los activos rusos	22/03
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)	20/03
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	13/03
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis	13/03
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	13/03
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	13/03
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee	13/03
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing	08/03
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference	06/03
Pacira BioSciences' Shares Rise After Company Posts Higher Q4 Non-GAAP Net Income, Revenue	29/02
Pacira: Q4 Earnings Snapshot	29/02
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02
Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024	29/02
Pacira BioSciences, Inc. Provides Earnings Guidance for the Year 2024	29/02
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q4 Revenue $181.2M, vs. Street Est of $180.9M	29/02
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q4 EPS $0.89, vs. Street Est of $0.85	29/02
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results	29/02
North American Morning Briefing : Fed's Preferred -2-	29/02
Pacira to Report 2023 Financial Results on Thursday February 29, 2024	22/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Pacira BioSciences, Inc.

Actions

PCRX

US6951271005

Autres langues

Filtres